{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:56:08Z","timestamp":1794020168485,"version":"4.8.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Achondroplasia is the most common form of short-limbed short stature of genetic origin. Most people with achondroplasia live fully independent, productive, and socially engaged lives. However, the condition is associated with several potential medical complications. Individuals with achondroplasia may experience medical, functional, and psychosocial challenges at different times in their life. The goal for lifelong care of individuals with achondroplasia is to optimize their physical and mental health through provision of individualized care and to promote participation and inclusion in society. In this article, as a tool for individuals with achondroplasia, their families, and their healthcare team, we provide a guided overview of the 2022 International Consensus Statement for management and care of individuals with achondroplasia. The International Consensus Statement recommendations are based on current, best available knowledge. We provide commentary on the recommendations from the perspective of both patients and physicians through addressing medical\/developmental considerations, the healthcare system, and psychosocial considerations.<\/jats:p>","DOI":"10.1186\/s13023-025-04189-y","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T10:44:10Z","timestamp":1768905850000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["An overview of the International Consensus Statement on achondroplasia"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8963-4736","authenticated-orcid":false,"given":"In\u00eas","family":"Alves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2804-5783","authenticated-orcid":false,"given":"Svein Otto","family":"Fredwall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9619-9071","authenticated-orcid":false,"given":"Penelope J.","family":"Ireland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6495-022X","authenticated-orcid":false,"given":"Morrys C.","family":"Kaisermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5105-8427","authenticated-orcid":false,"given":"Ravi","family":"Savarirayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"key":"4189_CR1","doi-asserted-by":"crossref","unstructured":"Savarirayan R, Ireland P, Irving M, Thompson D, Alves I, Baratela WAR, et al. International Consensus Statement on the diagnosis, multidisciplinary management and lifelong care of individuals with achondroplasia. Nat Rev Endocrinol. 2022;18:173\u201389.","DOI":"10.1038\/s41574-021-00595-x"},{"key":"4189_CR2","doi-asserted-by":"crossref","unstructured":"Pauli RM. Achondroplasia: a comprehensive clinical review. Orphanet J Rare Dis. 2019;14:1.","DOI":"10.1186\/s13023-018-0972-6"},{"key":"4189_CR3","doi-asserted-by":"crossref","unstructured":"Foreman PK, van Kessel F, van Hoorn R, van den Bosch J, Shediac R, Landis S. Birth prevalence of achondroplasia: a systematic literature review and meta-analysis. Am J Med Genet A. 2020;182:2297\u2013316.","DOI":"10.1002\/ajmg.a.61787"},{"key":"4189_CR4","doi-asserted-by":"crossref","unstructured":"Fredwall SO, Steen U, de Vries O, Rustad CF, Eggesb\u00f8 HB, Weedon-Fekj\u00e6r H, et al. High prevalence of symptomatic spinal stenosis in Norwegian adults with achondroplasia: a population-based study. Orphanet J Rare Dis. 2020;15:123.","DOI":"10.1186\/s13023-020-01397-6"},{"key":"4189_CR5","doi-asserted-by":"crossref","unstructured":"Okenfuss E, Moghaddam B, Avins AL. Natural history of achondroplasia: a retrospective review of longitudinal clinical data. Am J Med Genet A. 2020;182:2540\u201351.","DOI":"10.1002\/ajmg.a.61825"},{"key":"4189_CR6","doi-asserted-by":"crossref","unstructured":"Cheung MS, Mohnike K. Meeting report from 2nd ICCBH-ERN bond spinal complications in children and adults with achondroplasia workshop. In: Bone. Vol. 165. Dublin, Ireland; 2022. p. 116574. 2nd July 2022.","DOI":"10.1016\/j.bone.2022.116574"},{"key":"4189_CR7","doi-asserted-by":"crossref","unstructured":"Hoover-Fong J, Cheung MS, Fano V, Hagenas L, Hecht JT, Ireland P, et al. Lifetime impact of achondroplasia: current evidence and perspectives on the natural history. Bone. 2021;146:115872.","DOI":"10.1016\/j.bone.2021.115872"},{"key":"4189_CR8","doi-asserted-by":"crossref","unstructured":"Wright MJ, Irving MD. Clinical management of achondroplasia. Arch Dis Child. 2012;97:129\u201334.","DOI":"10.1136\/adc.2010.189092"},{"key":"4189_CR9","doi-asserted-by":"crossref","unstructured":"Legare JM, Liu C, Pauli RM, Alade AY, Hashmi SS, Campbell JW, et al. Achondroplasia natural history study (clarity): 60-year experience in cervicomedullary decompression in achondroplasia from four skeletal dysplasia centers. J Neurosurg Pediatr. 2021;28:229\u201335.","DOI":"10.3171\/2020.12.PEDS20715"},{"key":"4189_CR10","doi-asserted-by":"crossref","unstructured":"Oliver J, Lobban D, Dormer L, Walker J, Stephens R, Woolley K. Hidden in plain sight? Identifying patient-authored publications. Res Involv Engagem. 2022;8:12.","DOI":"10.1186\/s40900-022-00346-w"},{"key":"4189_CR11","doi-asserted-by":"publisher","first-page":"a036517","DOI":"10.1101\/cshperspect.a036517","volume":"10","author":"B Stevens","year":"2020","unstructured":"Stevens B. Impact of emerging technologies in prenatal genetic counseling. Cold Spring Harb Perspect Med. 2020;10:a036517.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"4189_CR12","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S2352-4642(23)00265-1","volume":"8","author":"R Savarirayan","year":"2024","unstructured":"Savarirayan R, Wilcox WR, Harmatz P, Phillips J 3rd, Polgreen LE, Tofts L, et al. Vosoritide therapy in children with achondroplasia aged 3\u201359 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Child Adolesc Health. 2024;8:40\u201350.","journal-title":"Lancet Child Adolesc Health"},{"key":"4189_CR13","unstructured":"A\/S AP. A clinical trial to evaluate efficacy and safety of TransCon CNP compared with placebo in infants (0 to <2 years of age) with achondroplasia. 2025. https:\/\/clinicaltrials.gov\/study\/NCT06079398. Accessed 18 Nov 2025."},{"key":"4189_CR14","doi-asserted-by":"publisher","first-page":"100566","DOI":"10.1016\/j.medj.2024.11.019","volume":"6","author":"R Savarirayan","year":"2025","unstructured":"Savarirayan R, Irving M, Wilcox WR, Bacino CA, Hoover-Fong JE, Harmatz P, et al. Sustained growth-promoting effects of vosoritide in children with achondroplasia from an ongoing phase 3 extension study. Med. 2025;6:100566.","journal-title":"Med"},{"key":"4189_CR15","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1002\/ajmg.a.38150","volume":"173","author":"J Hoover-Fong","year":"2017","unstructured":"Hoover-Fong J, McGready J, Schulze K, Alade AY, Scott CI. A height-for-age growth reference for children with achondroplasia: expanded applications and comparison with original reference data. Am J Med Genet A. 2017;173:1226\u201330.","journal-title":"Am J Med Genet A"},{"key":"4189_CR16","doi-asserted-by":"crossref","unstructured":"Merker A, Neumeyer L, Hertel NT, Grigelioniene G, Mohnike K, Hagen\u00e4s L. Development of body proportions in achondroplasia: sitting height, leg length, arm span, and foot length. Am J Med Genet A. 2018;176:1819\u201329.","DOI":"10.1002\/ajmg.a.40356"},{"key":"4189_CR17","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/ajmg.a.61974","volume":"185","author":"L Neumeyer","year":"2021","unstructured":"Neumeyer L, Merker A, Hagen\u00e4s L. Clinical charts for surveillance of growth and body proportion development in achondroplasia and examples of their use. Am J Med Genet A. 2021;185:401\u201312.","journal-title":"Am J Med Genet A"},{"key":"4189_CR18","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1002\/ajmg.a.38312","volume":"173","author":"L Tofts","year":"2017","unstructured":"Tofts L, Das S, Collins F, Burton KLO. Growth charts for Australian children with achondroplasia. Am J Med Genet A. 2017;173:2189\u2013200.","journal-title":"Am J Med Genet A"},{"key":"4189_CR19","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/j.1469-8749.2012.04234.x","volume":"54","author":"PJ Ireland","year":"2012","unstructured":"Ireland PJ, Donaghey S, McGill J, Zankl A, Ware RS, Pacey V, et al. Development in children with achondroplasia: a prospective clinical cohort study. Dev Med Child Neurol. 2012;54:532\u201337.","journal-title":"Dev Med Child Neurol"},{"key":"4189_CR20","doi-asserted-by":"crossref","unstructured":"Mayhew JF, Katz J, Miner M, Leiman BC, Hall ID. Anaesthesia for the achondroplastic dwarf. Can Anaesth Soc J. 1986;33:216\u201321.","DOI":"10.1007\/BF03010834"},{"key":"4189_CR21","doi-asserted-by":"crossref","unstructured":"Ok MS, Nagaraj UD, Mahmoud M. Foramen magnum stenosis and spinal cord compression in achondroplasia. Anesthesiology. 2019;131:396.","DOI":"10.1097\/ALN.0000000000002757"},{"key":"4189_CR22","doi-asserted-by":"crossref","unstructured":"White KK, Bompadre V, Goldberg MJ, Bober MB, Cho T-J, Hoover-Fong JE, et al. Best practices in peri-operative management of patients with skeletal dysplasias. Am J Med Genet A. 2017;173:2584\u201395.","DOI":"10.1002\/ajmg.a.38357"},{"key":"4189_CR23","doi-asserted-by":"crossref","unstructured":"Alade Y, Tunkel D, Schulze K, McGready J, Jallo G, Ain M, et al. Cross-sectional assessment of pain and physical function in skeletal dysplasia patients. Clin Genet. 2013;84:237\u201343.","DOI":"10.1111\/cge.12045"},{"key":"4189_CR24","doi-asserted-by":"crossref","unstructured":"Dhiman N, Albaghdadi A, Zogg CK, Sharma M, Hoover-Fong JE, Ain MC, et al. Factors associated with health-related quality of life (HRQOL) in adults with short stature skeletal dysplasias. Qual Life Res. 2017;26:1337\u201348.","DOI":"10.1007\/s11136-016-1455-7"},{"key":"4189_CR25","doi-asserted-by":"crossref","unstructured":"Saint-Laurent C, Garde-Etayo L, Gouze E. Obesity in achondroplasia patients: from evidence to medical monitoring. Orphanet J Rare Dis. 2019;14:253.","DOI":"10.1186\/s13023-019-1247-6"},{"key":"4189_CR26","unstructured":"Cleeland CS, Ryan KM. Pain assessment: global use of the brief pain inventory. Ann Acad Med Singap. 1994;23:129\u201338."},{"key":"4189_CR27","doi-asserted-by":"crossref","unstructured":"Ireland PJ, Savarirayan R, Pocovi T, Tate T, Coussens M, Tofts L, et al. Development of the screening Tool for Everyday mobility and symptoms (stems) for skeletal dysplasia. Orphanet J Rare Dis. 2021;16:40.","DOI":"10.1186\/s13023-021-01681-z"},{"key":"4189_CR28","doi-asserted-by":"crossref","unstructured":"Fredwall S, Allum Y, AlSayed M, Alves I, Ben-Omran T, Boero S, et al. Optimising care and follow-up of adults with achondroplasia. Orphanet J Rare Dis. 2022;17:318.","DOI":"10.1186\/s13023-022-02479-3"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-04189-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04189-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04189-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T12:22:49Z","timestamp":1769689369000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-025-04189-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4189"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-04189-y","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"assertion":[{"value":"26 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"IA and PI have no competing interests to report. SOF has received consulting fees from BioMarin paid to his institution and is an investigator in clinical trials for Ascendis Pharma A\/S and QED Therapeutics. MH has no competing interests relevant to this publication but reports that he is an employee of Merck; Merck has no commercial or research involvement in achondroplasia. MCK has no competing interests relevant to this publication but reports that he is an employee of GlaxoSmithKline; GlaxoSmithKline had no involvement in this work. RS has received consulting fees and grants from BioMarin and was an investigator in clinical trials for achondroplasia for Ascendis Pharma A\/S, BioMarin, and QED Therapeutics.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34"}}